Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.

Matthew J KlingConnor N GriggsErin M McIntyreGracey AlexanderSutapa RayKishore B ChallagundlaShantaram S JoshiDon W CoulterNagendra K Chaturvedi

Published in: BMC cancer (2021)

Together, our findings demonstrate synergistic efficacy of JQ1 or OTX-015 and temsirolimus against MYCN-driven NB, by dual-inhibition of MYCN (targeting transcription) and mTOR (targeting translation). Additional preclinical evaluation is warranted to determine the clinical utility of targeted therapy for high-risk NB patients.

Keyphrases

cancer therapy
end stage renal disease
drug delivery
cell proliferation
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
signaling pathway
patient reported outcomes
patient reported